
Commentary|Videos|December 15, 2023
Dr. Kukreja on key kidney cancer research presented at SUO 2023
Author(s)Urology Times staff
Janet Kukreja, MD, outlines key kidney cancer research that was presented at this year’s Society of Urologic Oncology Annual Meeting.
Advertisement
In this video, Janet Kukreja, MD, outlines key kidney cancer research that was presented at this year’s
- Poster 6: SWOG S1931 (PROBE): Phase III randomized trial of immune checkpoint inhibitor (ICI) combination regimen with or without cytoreductive nephrectomy (CN) in advanced renal cancer [NCT04510597] – Hyung Kim, MD
- Poster 7: Safety of partial and radical nephrectomy for complex locally advanced renal cell carcinoma after neo-adjuvant immune checkpoint inhibition (durvalumab +/- tremelimumab) – Joseph Zabell, MD
- Poster 101: Socioeconomic and demographic disparities in immunotherapy for advanced clear cell renal cell carcinoma – Levi Holland, MD
- Poster 13: Limited utility of quantitative thresholds on 99MTC-sestamibi SPECT/CT for distinguishing renal cell carcinoma from oncocytic renal masses – Robert S. Wang, MD
- Poster 103: Comprehensive Immunogenomic Evaluation of Patients Undergoing Consolidative Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Patients Treated with Immune Checkpoint Blockade – Stephen Reese, MD
Advertisement
Related to this article

Muhammed A. Moukhtar Hammad, MBBCh, MSc, discusses real-world trends in baseline erectile dysfunction treatment across AUA sections before minimally invasive BPH procedures.

Earlier genetic testing in men with very low sperm counts may spare unnecessary testing or surgery, according to Ronald Anglade, MD.

Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.

VOLGA results raise the question of treatment de-intensification in perioperative MIBC care, according to Suzanne B. Merrill, MD, FACS.

Patient goals, disease features, and response to prior therapy guide treatment choices across high-risk NMIBC, according to Suzanne B. Merrill, MD, FACS.

Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.

BCG monotherapy and a high-quality TURBT remain the foundation for BCG-naive high-risk NMIBC, according to Vignesh T. Packiam, MD.
Advertisement
Advertisement
Trending on Urology Times
1
Rethinking Testosterone Therapy After the FDA Label Revisions
2
FDA clears phase 1/2 trial of androgen receptor antagonist in mCRPC
3
BPH treatment patterns: Understanding regional differences in baseline ED treatment
4
Gedatolisib plus darolutamide: Early findings in mCRPC
5



